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ABSTRACT   
Levodopa-induced dyskinesia are common complications in Parkinson disease. Pathogenic 
mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa-to-
dopamine conversion in serotonergic neurons, hyperactivity of cortico-striatal glutamatergic 
transmission and overstimulation of nicotinic acetylcholine receptors on dopamine-releasing 
axons. Delay in initiating levodopa is no longer recommended as dyskinesia development is a 
function of disease duration rather than cumulative levodopa exposure. We review current and 
in-development treatments for peak-dose dyskinesia but suggest that improvements in levodopa 
delivery alone may reduce its future prevalence.  
 
Keywords: Parkinson’s disease; Motor control; Dyskinesia 
 
Domain: Neuroscience, Clinical Research 
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INTRODUCTION 
Dyskinesia, often referred to as levodopa-induced dyskinesia (LID) to recognize levodopa as the 
major contributor, is a motor complication arising in patients with Parkinson disease (PD) on 
chronic levodopa treatment, largely in a dose-dependent fashion—except when given as an 
infusion, such as in levodopa/carbidopa intestinal gel.
1
 LID is phenomenologically recognized as 
chorea/choreathetoid movements appearing initially on the more affected body side. LID occurs 
in 40% of patients after 4 years on levodopa treatment, with a risk especially high in younger 
patients treated with higher doses of levodopa.
2
  
 
This review focuses on aspects of phenomenology, pathophysiology, and therapeutics that have 
undergone revisions or updates in recent years, emphasizing those of most relevance for modern 
clinical care and future research. We highlight the under-recognized diphasic dyskinesia, which 
is often mischaracterized as a peak-dose phenomenon and therefore mismanaged. We review 
evidence that corrects the misinterpretation of prior clinical trial data surmising LID as a function 
of duration of levodopa exposure rather than duration of disease, justifying the inappropriate but 
still lingering recommendation to postpone levodopa treatment as long as possible to ―delay‖ the 
appearance of LID.
3
 We also review the latest pathophysiologic concepts at the molecular, 
synaptic, and network levels, in order to provide the rationale for currently available as well as 
emerging treatments.  
 
Peak-dose vs. diphasic dyskinesia 
Peak-dose dyskinesia. Chorea that may be generalized or affecting the more affected side or 
upper body often occurs during the therapeutic window of a levodopa dose cycle (ON 
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medication state) (Fig 1; Supplementary Video 1). Cervical-predominant chorea may appear as 
―head bobbing‖ (classically understood to be rhythmic to-and-fro movements of the head), but 
close inspection discloses no rhythmicity to these movements. With time, many patients 
demonstrate little or no ―therapeutic window,‖ which results in peak-dose dyskinesia throughout 
the dose-related benefit—referred to as ―square wave‖.4 While ―classic‖ peak-dose dyskinesia is 
often associated with truncal and upper-limb predominant chorea, lower-body predominant 
chorea, considered ―classic‖ diphasic, may predominate (Supplementary Video 2). Isolated 
orofacial dyskinesia appears to be more frequent in older-onset PD.
4
   
 
Diphasic dyskinesia. This variant is also referred to as beginning- and end-of-dose or transitional 
dyskinesia, because it occurs as levodopa is becoming effective, toward the beginning of a dose 
cycle, or as it begins to wear off, toward the end of a dose cycle (Fig 1; Supplementary Video 
3). Diphasic dyskinesia tends to have a more variable topographical distribution and be reported 
as more troublesome compared with peak-dose dyskinesia. When exclusively affecting the legs, 
ballistic or stereotypic alternating movements may predominate (Fig 2; Supplementary Video 
4).
5
 Some of these movements may give rise to bizarre but highly stereotypical gait patterns.
6
 It 
is distinct from but can evolve into wearing-off dystonia, typically expressed as toe curling, 
sometimes with plantar flexion or inversion.
7
 A similar common low-dose phenomenon is early-
morning dystonia (Supplementary Video 5).  
 
Dyskinesia and levodopa 
Levodopa is necessary but insufficient to generate LID. LID requires a pulsatile delivery (short 
half-life), a presynaptic nigrostriatal degeneration, and a relatively preserved post-synaptic 
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nigrostriatal system. In most atypical parkinsonisms, such as progressive supranuclear palsy, 
where the post-synaptic system is affected, levodopa rarely induces dyskinesia. While there is a 
dose-dependent increase in peak-dose dyskinesia when levodopa is administered orally,
8
 such 
effect is lost when delivered continuously. Indeed, continuous levodopa infusion typically 
reduces pre-existent LID, even with a dose higher than that used orally.
1
 This may be due to 
favorable pharmacodynamic effects of continuous levodopa delivery despite a higher area-under-
the-curve and a more physiologic (tonic) stimulation of dopamine receptors.  
 
Although levodopa is necessary for dyskinesia development, the clock for this complication 
begins to tick at disease onset rather than upon levodopa initiation. Long-term studies have 
consistently shown that motor complications develop with the same frequency and severity 
irrespective of whether levodopa was initiated early or late.
9
 This was best demonstrated by a 
study on levodopa-initiation in sub-Saharan African PD patients, whose longer delay in receiving 
levodopa (mean, 4.2 years) than matched patients in Italy (1.8 years)
10
 was associated with a 
shorter dyskinesia-free period. The exact same finding has repeatedly been reported in 
preclinical settings using both rodent and primate models of parkinsonism and dyskinesia, most 
animals being capable of displaying dyskinesia at first levodopa exposure if the lag time between 
lesion establishment and pharmacological challenge is long enough.
11
 Such data have led to a 
modification of the concept of priming, proposing that it is the direct and intrinsic consequence 
of the loss of dopamine innervation of the striatum, with the first injections of dopaminergic 
drugs sensitizing but not inducing it.
11
 The evidence collectively suggests that disease severity 
and levodopa dose are more important than duration of levodopa treatment for the development 
of dyskinesia in PD.
12
 Furthermore, young age at onset, low body weight, female sex, and more 
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 7 
severe motor disability may represent important vulnerabilities and highlight an important 
contribution of levodopa dose in these high-risk groups.
13
 Although greater risk for LID may be 
accrued in certain clinical subtypes (e.g., akinetic-rigid compared to tremor-dominant
14
) and 
genetic polymorphisms (e.g., the Val158Met variant of COMT
15
), these associations remain 
tentative and at present have little clinical application. Nevertheless, the bizarre but highly 
stereotypical gait associated with diphasic dyskinesia in young-onset PD patients may be more 
common in patients with PRKN (Parkin, PARK2) mutations.
16
 Of note, diphasic dyskinesia has 
been found to be associated with the DRD3 p.S9G variant, with the AA genotype shortening it’s 
time to onset after levodopa initiation.
17
 
 
Dyskinesia and disability  
With therapeutic doses of levodopa, hypokinetic disability might be replaced with dyskinetic 
disability. As hypokinesia is generally more bothersome, patients usually prefer the dyskinetic to 
the parkinsonian state.
18
 Although an undesirable outcome, dyskinesia is also generally a marker 
of treatment success: the point at which dopaminergic replacement has reached and surpassed the 
therapeutic window. PD patients who have never exhibited dyskinesia may be undertreated with 
potentially greater net disability, since the onset and offset of therapeutic and dyskinetic 
thresholds have been demonstrated to be similar.
 12
 Advanced levodopa-treated PD patients, thus, 
may alternate between tremor, gait freezing, or other parkinsonian features and LID (peak-dose 
and/or diphasic), with no ―sweet spot‖ in between.  
 
The highest tolerable doses of the dopamine agonists (pramipexole, ropinirole, rotigotine) exhibit 
lower efficacy than levodopa and may induce or worsen dyskinesia once patients begin 
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concurrent oral levodopa treatment. Therefore, rather than delaying dyskinesia, as proposed in 
the CALM-PD
19
 and REAL-PET
20
 studies, dopamine agonists are mostly incapable of extending 
their effect into and beyond the therapeutic window, defined by a period of optimal response to 
levodopa, to generate dyskinesia when given without levodopa. Importantly, the CALM-PD and 
REAL-PET studies, comparing pramipexole and ropinirole, respectively, to levodopa as early 
monotherapies, showed superior motor improvement and quality of life in the levodopa-treated 
groups. These endpoints were deemphasized whereas the greater incidence of dyskinesia in the 
levodopa-treated arm emphasized, ushering the ―levodopa-sparing‖ by means of early initiation 
of dopamine agonists to avoid or postpone LID. Separately, the PD-MED trial (long-term 
comparison of L-dopa, dopamine agonists and monoamine oxidase B inhibitors as first-line 
treatment on 1,620 PD patients, with mean age ~70 years, recruited over 9 years and followed 
for a median of 3 years) also showed that dopamine agonists provided less overall benefit than 
levodopa despite the fact that the levodopa group had significantly more dyskinesia.
21
 
 
PATHOPHYSIOLOGY 
The current model of LID pathophysiology, mainly focused on peak-dose dyskinesia, 
hypothesizes the following events at the striatal level: pulsatile stimulation of dopamine 
receptors, excessive presynaptic swing of dopamine leading to increased receptor occupancy,
22
 
dissociation between low intrastriatal dopamine and high plasma and extracellular levodopa,
23
 
downstream changes in the post-synaptic compartment, and abnormalities in non-dopaminergic 
neurotransmitters. All of these events cause changes in the firing patterns and the oscillatory 
activity between the basal ganglia and the motor cortex, leading to excessive disinhibition of 
thalamocortical neurons and over-activation of the motor cortex. Understanding these 
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mechanisms of LID at network and synaptic levels can assist in the development of 
neuromodulatory or pharmacological interventions.   
 
Network mechanisms 
The mechanism of LID at the network level has been studied in PD patients using a variety of 
neurophysiological and neuroimaging methods, including local field potentials (LFP), 
transcranial magnetic stimulation (TMS),
24
 voxel-based morphometry (VBM), and functional 
magnetic resonance imaging (fMRI).
25, 26
 Classically, an excessive reduction of the firing rate in 
the globus pallidus pars interna (GPi) and in the subthalamic nucleus (STN) secondary to 
nonphysiological stimulation of dopamine receptors in the denervated striatum has been 
associated to LID.
27
 Registration of LFP in animals and humans suggests that alterations in firing 
patterns, including changes in synchronization, may be more relevant than changes in firing 
rates. Animal studies show a strong coherence between the basal ganglia and frontal cortical 
activity during LID. Limited data from human subjects have examined the coherence between 
cortical and subcortical structures in patients treated with deep brain stimulation (DBS). Unlike 
the hypersynchronous activity in the beta-band (20-30 Hz) associated with the akinetic or ―OFF‖ 
medication state, the hyperkinetic LID state is characterized by a reduction of power in the 
beta-band LFP activity,
28
 hypersynchronous gamma oscillations between 60 and 90 Hz in the 
motor cortex and STN, and strong phase coherence between them, with no or minimal influence 
of voluntary movements.
29
 Indeed, a novel adaptive (closed-loop) DBS device reduced LID by 
decreasing the voltage of stimulation when detecting a decrease in beta-band activity in the 
STN.
30
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An inconsistency of the classical firing-rate model in predicting LID is that it does not take into 
account the strong connections between the basal ganglia and the motor cortices. Abnormal 
synaptic plasticity has been demonstrated by TMS studies to arise from the primary motor cortex 
(M1).
24, 31
 Beyond M1, functional and structural abnormalities have also been demonstrated by 
structural and functional neuroimaging in motor areas involved in motor planning and inhibition, 
such as the supplementary motor area (SMA) and inferior frontal cortex (IFC) (Table 1, figure 
3). 
 
Molecular and synaptic mechanisms 
LID-generating mechanisms at the synaptic level show biochemical abnormalities associated 
with LID in dopaminergic
22
 and non-dopaminergic receptors
32
 and in striatal enzymes regulating 
dopaminergic signaling
33
 (Fig 3). In this regard, alterations of the serotonergic system,
34
 
phosphodiesterase 10A (PDE10A),
33
 and the glutamatergic system
35
 support a pathogenic role of 
N-methyl-D-aspartate (NMDA) receptors in LID development (Fig 4).  
 
The role of dopamine. Dopamine receptors occupy a prominent role in the pathophysiology of 
LID, even if any relationship between the two is affected by factors such as age and genetic 
background.
36
 D1 receptor activation is a key factor for the development of LID. While a 
preferential selectivity by oral dopamine agonists for D2-D3 receptor subtypes with no affinity 
for D1 and D5 receptors
37
 could explain for their lower prodyskinetic effects, activation of 
striatal D3Rs exert a synergistic effect on D1R-mediated transmission through direct 
intramembrane interaction.
38
 Thus, the binding of pramipexole to D3R boosts D1R function, 
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which explains both its antiparkinsonian efficacy and its prodyskinetic effects. Rotigotine has 
also been shown to be a potent agonist at D1 receptors.
39
 
 
LID is associated with several molecular changes at the striatal level likely mediated by 
overactivation of dopamine D1 receptors such as increased FosB and prodynorphin messenger 
RNA expression
40
 and the initiation of two processes down-stream of likely linked to ERK 
(extracellular signal-regulated kinase) signaling pathways: an abnormal activation of mitogen- 
and stress-activated kinase-1 (MSK-1) and a phosphorylation of histone H3.
41
 D1/DARPP-32 
activation by levodopa induces phospho-ERK translocation in the nucleus and the consequent 
activation of MSK-1 which has a key role in the regulation of synaptic plasticity and 
transcriptional activity.
42
 Abnormal regulation of MSK-1 facilitates the induction of LID and 
increase in striatal ∆FosB, possibly mediated by increased histone H3 phosphorylation at the 
FosB promoter.
43
 The possible differential role of direct and indirect pathway spiny neurons in 
LID has been recently shown in a study using a new chemogenetic technology:
44
 stimulation of 
Gq-coupled human M3 muscarinic receptors in direct-pathway spiny neurons caused a beneficial 
anti-parkinsonian effect in mice and a surge of LID; indirect pathway activation did not. 
 
LID is associated with cortico-striatal plastic alterations at the synaptic level, shown by a 
reversal of long-term potentiation (LTP) or loss of ―synaptic depotentiation‖.45 The loss of this 
homeostatic synaptic mechanism was found to be associated with increased activity of the 
molecular cascade downstream of the D1 dopamine receptors leading to an increase in 
DARPP-32 phosphorylation.
45
 A spike-timing dependent protocol has revealed that the 
homeostatic adaptation in intrinsic excitability of spiny neurons is lost in mice with LID, 
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suggesting an alteration of the number of cortico-striatal synapses
46
 and a switch from 
bidirectional to unidirectional striatal plasticity.
47
 An M4 muscarinic receptor allosteric 
modulator enabled LTP reversal and reduced dyskinetic behaviors in a primate model, 
suggesting muscarinic receptors as potential targets for pharmacotherapy against LID.
48
 In line 
with these observations, a reduced bidirectional plasticity has also been observed in dyskinetic 
PD patients in the substantia nigra pars reticulata by LFP recording with DBS electrodes
49
 and in 
the cerebral motor cortex using TMS.
50
  
 
LID can also be associated with abnormal structural synaptic plasticity. In fact, both D1 and D2 
receptor-positive spiny neurons have diminished spine density in the rodent-denervated 
striatum.
51
 Surprisingly, however, long-term levodopa treatment causing dyskinesia restores 
spine density in D2 but not in D1 receptor-positive spiny neurons, suggesting that these 
morphological changes might represent structural underpinnings of LID in PD.   
 
The role of glutamate. Hyperactivity of cortico-striatal glutamatergic transmission has been 
shown in animal models of PD and postulated in PD patients with LID, possibly resulting from 
receptor and molecular alterations at pre- and post-synaptic levels due to dopaminergic loss.
52
 
Dyskinetic rats have high striatal levels of the NMDA receptor GluN2A subunit but low levels of 
the GluN2B subunit in the post-synaptic compartment, suggesting a pathological redistribution 
of receptors between synaptic and extra-synaptic glutamatergic membranes in LID.
53
 An altered 
ratio of synaptic striatal GluN2A/GluN2B-containing NMDA receptors has also been found in 
dyskinetic monkeys and in post-mortem tissue from dyskinetic PD patients. A cell-permeable 
peptide interfering with the GluN2A subunit interaction with protein post-synaptic density 
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protein 95 (PSD-95) reduced dyskinesia in LID models.
54
 Recent studies identified a possible 
molecular partner in LID modulation through GluN2A subunits.
55
 The interaction between the 
synaptic protein Rabphilin 3A (Rph3A) and GluN2A-containing NMDA receptors is increased 
in parkinsonian rats developing dyskinesia. A cell-permeable peptide interfering with this 
interaction decreases LID.
55
  
 
The role of the serotonergic system. In the face of striatal dopamine denervation, levodopa 
conversion to dopamine migrates to non-dopaminergic cells, particularly serotonergic raphe 
nuclei neurons.
56
 Dopamine is then released by serotonergic neurons in a nonphysiological, 
unregulated manner in the extra-synaptic cleft where it might act as a ―false transmitter‖, causing 
abnormal and pulsatile activation of striatal dopamine receptors.
57
 Reducing abnormal dopamine 
release via presynaptic  serotonergic 5-HT1A agonists can decrease dyskinesia in parkinsonian 
models.
58
 Moreover, ablation of serotonergic transmission reduced LID
59
 whereas transplants of 
serotonin-enriched grafts worsened LID in parkinsonian rats.
60
  
 
The role of other non-dopaminergic mechanisms. Within the basal ganglia, chronic pulsatile 
dopamine receptor stimulation leads to alterations in cholinergic, opioid, histaminic, adrenergic, 
and cannabinoid function.  
 
Acetylcholine is integral to striatal function. Cholinergic interneurons are modulated by 
dopamine and striatal dopamine release is regulated via a di-synaptic pathway involving cortical 
and thalamic glutamatergic inputs to the cholinergic interneurons with stimulation of nicotinic 
acetylcholine receptors on nigrostriatal axons.
61
 Agonists at subtypes of nicotinic receptors have 
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been shown to reduce LID.
62
 The mechanism may involve reducing dopamine release via a 
chronic desensitization or down-regulation of nicotinic receptors.
63
 Muscarinic cholinergic 
receptor involvement in LID is less clear with cholinergic antagonists at M4 receptors possibly 
reducing dystonia but exacerbating chorea. Histamine H2 receptors located within the striatum 
may reduce LID via modulation of acetylcholine.
64
  
 
The opioid peptide precursors, pro-enkephalin and pro-dynorphin, are co-transmitters in the 
GABAergic striatopallidal pathways and function as neuromodulators. Many studies have shown 
increased levels of pro-dynorphin breakdown products linked to the expression of LID in animal 
models of PD.
65
 Mu-subtype opioid receptors appear to modulate activity of the direct 
striatopallidal pathway and antagonists at this receptor may reduce LID.
66
 Opioid signaling is 
complex, however, and other authors have shown increased LID with some opioid antagonists.
67
 
 
The cannabinoid system is implicated in basal ganglia function, with endocannabinoids involved 
in glutamate/dopamine signaling and striatal plasticity.
68
 Cannabinoid CB1 receptors are also 
highly expressed in the internal segment of the GPi, the output region of the basal ganglia.
69
 The 
pharmacology is complex with both CB1 agonists and antagonists reducing LID.
70
 Targeting the 
enzymatic breakdown of cannabinoids using fatty acid amide hydrolase inhibitors may also 
reduce LID.
71
  
 
Noradrenergic signaling may also be involved in LID, although the mechanisms are unclear. 
Both alpha- and beta-adrenergic receptor antagonists can reduce LID in animal models.
72
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MANAGEMENT 
Available oral pharmacological treatments 
Diphasic LID is managed in a manner similar to wearing-off symptoms: increasing the 
individual levodopa doses, converting to a long-acting formulation of levodopa, or adding 
longer-acting dopaminergic medications (e.g., a monoamine oxidase B [MAO-B] inhibitor, 
catechol-O-methyltransferase inhibitor, or dopamine agonist). No clinical trials focused on 
diphasic dyskinesia have been reported. Anecdotally apomorphine was observed to reduce the 
duration of diphasic dyskinesia at doses higher than necessary to induce an ―ON‖ phase.73 
 
Below we summarize the available strategies assessed for direct effect against peak-dose LID for 
which sufficient evidence exists. We do not include drugs for which any anti-dyskinetic effect 
has been assumed indirectly, emerging from the ―ON time without troublesome dyskinesia‖ 
endpoint used in clinical trials (e.g., safinamide) or because of a reduction in dopaminergic tone 
in ―levodopa-sparing‖ interventions (e.g., dopamine agonists). 
 
Amantadine. An NMDA antagonist, amantadine is the most widely used oral therapy for 
dyskinesia. The International Parkinson and Movement Disorder Society Evidence-based 
Medicine Committee classified amantadine as ―efficacious‖ in the treatment of dyskinesia.74 The 
safety of amantadine is considered acceptable, although side effects such as confusion, 
hallucinations, ankle edema, constipation, and dry mouth narrow the therapeutic window. ADS-
5102 (amantadine extended release) was recently approved by the FDA ―for the treatment of 
dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant 
dopaminergic medications.‖75 Compared with placebo, ADS-5102 274-mg significantly reduced 
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dyskinesia as measured by the Unified Dyskinesia Rating Scale, treatment difference, –7.9 
(P < .001).75 Additional studies will be needed to investigate the comparative efficacy between 
ADS-5102 and immediate-release amantadine. 
 
Clozapine. Off-label targeting of 5HT2A/2C receptors by this atypical antipsychotic has shown 
anti-LID efficacy in a single randomized controlled trial, without worsening PD motor 
symptoms, and has also been considered ―efficacious‖.76 Another proposed mechanism for its 
antidyskinetic action in low doses is D1 receptor antagonism.
77
 However, clinical usefulness is 
limited due to safety issues.
74
  
 
Levetiracetam. Off-label levetiracetam has yielded conflicting anti-dyskinetic efficacy and 
tolerability.
78
 The  purported anti-LID mechanism of action includes a change in the expression 
of certain transcription factors in the striatum. 
 
Pharmacological treatments in clinical development 
Several drugs with a variety of potentially relevant mechanisms of action, targeting 
receptors/neurotransmitters within the basal ganglia, are at various stages of clinical development 
(Table 2). Selection of potential symptomatic therapies for the management of PD has benefited 
from studies on the MPTP-treated macaque monkey, an excellent phenocopy of the motor 
symptoms and side effects of dopaminergic therapies.
79
 This model has been widely used in the 
preclinical evaluation of the various experimental therapeutics.
79
 Targets under evaluation 
exclusively in preclinical models are beyond the scope of this review. 
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Serotonergic targets. Although mixed agonists for both 5-HT1A and 5-HT1B receptors prevent 
the expression of LID, they may also reduce the therapeutic effect of levodopa.
80
 Indeed, despite 
reducing dyskinesia the 5-HT1A agonist sarizotan failed in phase III studies partly due to 
worsening of motor symptoms.
81
 Phase IIb studies of the clinically available 5-HT1A agonists, 
buspirone
82
 and eltoprazine
83
 are ongoing (clinicaltrials.gov NCT02617017 and NCT02439125, 
respectively). The advantage of both of these agents is their rapid clinical availability if efficacy 
and tolerability are demonstrated in these studies.  The added potential to reduce anxiety with 
such 5-HT1A agonists represents an additional benefit to PD subjects.  
 
Novel glutamate targets. Tolerability of glutamatergic agents has been a major issue to date, with 
off-target side effects including confusion, hallucinations and ataxia. As noted above, the longer 
acting preparation of the NMDA antagonist, amantadine ADS-5102, was recently approved by 
the FDA. A second long-acting amantadine HCL extended release was also recently approved 
but no details of clinical studies have been reported to date. Their potential advantage is 
theoretically less night-time confusion/hallucinations, but this has not been examined in direct 
comparison with standard amantadine. Recent studies of allosteric modulators of NMDA 
receptors have also been suggested to be better tolerated due to more selective basal ganglia 
targeting and wider therapeutic index.
84
 Abnormal cortico-striatal plasticity could theoretically 
be restored in part by the use of metabotropic glutamate receptor 5 (mGluR5) negative allosteric 
modulators, which reduce LID in rodent and primate models.
85, 86
 Early clinical studies of several 
mGluR5 antagonists showed some short-term antidyskinetic benefits but side effects of 
worsened PD motor symptoms has limited further development .
87
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Many other targets have been previously investigated in phase II/III clinical trials but these have 
either failed to reduce LID to a significant or clinically meaningful level compared to placebo or 
they have been poorly tolerated. Several challenges exist in the translational field for novel drugs 
to reduce LID, ranging from animal models to clinical trial designs to the availability of 
clinically safe agents required to evaluate the target of interest. Future strategies in the field thus 
need to address these issues with improved translational methodology (including animal models, 
dyskinesia rating scales and factors related to the heterogeneity of PD) as well as technology to 
aid in the measurement of LID and the use of artificial intelligence to increase the scope of 
potential targets to evaluate.
88
  
 
Advanced therapies (requiring invasive interventions) 
Due to the paucity of optimal oral pharmacological treatments for LID, three advanced treatment 
strategies have been developed: DBS, infusion of levodopa-carbidopa intestinal gel (LCIG), and 
continuous subcutaneous apomorphine infusion (CSAI).   
 
Deep brain stimulation. DBS is an invasive neurosurgical technique that delivers continuous 
electrical stimulation in specific brain areas by means of electrodes connected to an implantable 
pulse generator placed in the upper chest. Two main targets are used to treat LID in PD: the STN 
and the GPi.
89
 STN DBS has a profound ameliorative effect on LID due to at least 3 
mechanisms: 1) reduction of medications by 50-60%, as consistently seen by many prospective 
studies;
90
 2) stimulation of pallido-thalamic fibers in the zona incerta; and 3) plastic changes of 
the basal ganglia circuits that modulate levodopa responsiveness. A longstanding debate on the 
perceived superiority of STN over GPi inspired the execution of randomized prospective studies. 
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The meta-analysis of 3-year results of these comparative studies concluded that the two targets 
are comparable in the short term, but GPi is significantly better than STN in reducing LID.
91
 This 
finding confirms that GPi-DBS has a direct and profound anti-dyskinetic effect, regardless of any 
post-surgical modification in the dosage of dopaminergic therapies.  
 
Infusion of levodopa-carbidopa intestinal gel. LCIG allows the continuous infusion and reliable 
absorption of levodopa in the jejunal lumen, leading to sustained plasma levels. The system 
requires the endoscopic placement of a gastrostomy tube with an inner jejunal extension (PEG-
J), connected to a pump that holds replaceable cassettes of 2 g of levodopa. Retrospective studies 
and recent prospective trials have confirmed a significant reduction in LID.
92
 A post-hoc analysis 
of the 1-year data from LCIG pivotal studies in the subgroup of patients defined by ≥1 hour of 
ON time with troublesome dyskinesia demonstrated a reduction compared to baseline within this 
small cohort (n=144) despite higher total daily levodopa doses, suggesting a beneficial 
pharmacodynamic effect.
1
 Some LCIG patients may develop disabling diphasic LID in the 
morning and at the end of the day when levodopa levels rise and wear off, respectively.
93
 
Diphasic LID may be misinterpreted as peak-dose in some LCIG-treated PD patients (see 
Supplementary Video 3); their proper management requires increasing the dose of LCIG or 
adding other dopaminergic medications.
93
  
 
Continuous subcutaneous apomorphine infusion. Apomorphine is the only dopamine agonist 
administered subcutaneously, with the strongest D1 and D2 receptor affinity and shortest half-
life. A meta-analysis of 390 patients from 21 uncontrolled open-label studies over a mean time 
frame of 24.8 months (6–57 months) reported a mean LID reduction of 36%.94 The improvement 
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in LID severity depends in part on the extent to which oral dopaminergic medications with short 
half-life, such as levodopa, can be replaced by CSAI. In some cases this may require doses that 
are not tolerated, especially by elderly patients (e.g., confusion, psychosis, worsening of 
coexisting dysautonomia). Also, a common long-term complication of infusion is the occurrence 
of subcutaneous nodules. As a result, many centers in Europe use CSAI as a bridge treatment for 
fluctuating patients waiting to receive LCIG or DBS.
95
 This treatment modality is under 
evaluation in the US. 
 
To date, no randomized studies comparing the aforementioned 3 strategies have been performed. 
A study comparing STN DBS and LCIG reported an overall similar short-term effect on motor 
fluctuations although STN DBS may have been more effective against LID and associated with 
fewer adverse events.
96
 A pharmacological study comparing the acute and chronic effects of 
levodopa in a relatively small group of patients receiving either STN DBS, LCIG, or CSAI 
concluded that DBS was the best strategy for LID reduction.
97
  
 
Conclusions and future directions  
LID is one of the most studied but also least optimally managed treatment complications in PD. 
A limitation of clinical research rests in the difficulty in categorizing dyskinesia as peak-dose 
versus diphasic, given the phenomenological overlap. This has resulted in combining patients 
with different dyskinesia types and presumably different pathophysiologic mechanisms in 
clinical studies. Further work is needed to develop consensus guidelines for translating candidate 
therapies from clinical trials, proper LID models to guide drug development, and levodopa 
dosing and formulations to extend half-life. In addition, one important challenge to the 
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establishment of effective anti-dyskinetic therapies is the high placebo effect demonstrated in a 
number of studies.
98
 Rigorous, placebo-controlled trials will be important to better define the true 
treatment effect of any future intervention. 
 
The current state of therapy for LID is promising, with numerous pharmacologic and 
nonpharmacologic treatment options. Besides the newly approved extended-release oral 
formulation of amantadine, a range of molecular and neuromodulative therapies are under 
evaluation in the therapeutic pipeline. It is conceivable that future improvements in levodopa 
delivery alone, through long-acting levodopa preparations or infusion systems,
99
 may prevent the 
pharmacodynamic alterations associated with short-acting oral levodopa, and thus lower the 
prevalence of LID if initiated early. 
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Figure legends 
 
Figure 1.  Time course of diphasic dyskinesia according to 3 different theoretical plasma 
levodopa concentrations. This diagram illustrates the 4 theoretical pharmacokinetic states of a 
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single dose of levodopa (LD) as it increases (Y axis) over a 4-hour approximate time horizon 
between LD doses (X axis; although shown of similar magnitude, the width of each state is 
variable within and between patients). The therapeutic window (ON state, optimal clinical 
benefits) becomes virtual with disease progression, encroached by the sub- and supra-therapeutic 
windows. The subtherapeutic window is divided into the OFF (loss of clinical benefits with 
reemergence of parkinsonian features) and ―transitional‖ states. The latter may result in periods 
of diphasic dyskinesia (A, at both ends of the LD dose cycle) or longer, more disabling diphasic 
dyskinesia states (C) that could be mistaken for peak-dose square wave response (A, during the 
peak concentration). Pharmacotherapeutic strategies will differ in each scenario: LD dose should 
be reduced (or amantadine considered) in A but increased in C; LD dose interval may be 
shortened in B. An acute apomorphine or levodopa challenge can resolve uncertainty as it 
reduces or eliminates diphasic dyskinesia but leaves unchanged or worsens peak-dose 
dyskinesia.  
DiDysk = diphasic dyskinesia; LD = levodopa (adapted from Verhagen Metman and Espay, 
Neurology 2017); OFF: reemergence of parkinsonian features; ON: optimal clinical benefit.
100
 
 
Figure 2.  Common topographic patterns among various forms of dyskinesia in Parkinson 
disease. Right-sided onset of disease is assumed for all cases. A. Peak-dose levodopa-induced 
dyskinesia tends to involve the upper trunk, neck, and arms, particularly on the more affected 
side; B. Hemidyskinesia with arm-greater-than-leg involvement can also be a manifestation of 
peak-dose dyskinesia, especially among young-onset PD patients; C. Diphasic dyskinesia affects 
the legs to a greater extent than any other body part; D. Unilateral foot dystonia on the more 
affected side is the typical manifestation of OFF dystonia (still a low-dose phenomenon); 
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E. Facial choreoathetotic movements and hand posturing may occur in advanced PD patients; 
F. Facial dystonia with feet dyskinesias are a topographical distribution atypical for PD and 
suggestive of multiple system atrophy. Darker shades of gray emphasize greater severity. (Figure 
commissioned to Martha Headworth. Adapted with permission from Espay.
101
) Printed with 
permission from Mayfield Clinic.  
MSA= multiple system atrophy; PD = Parkinson disease. 
 
Figure 3.  Functional and structural network abnormalities in motor cortical areas and 
their connections with the basal ganglia and the cerebellum. At the network level, the 
supplementary motor area (SMA) and the inferior frontal cortex (IFC), which are involved in 
motor programming and inhibition, have been shown to be dysfunctional or structurally 
abnormal in Parkinson disease-associated levodopa-induced dyskinesia. The solid red arrow 
refers to decreased inhibition from the cerebellum to the primary motor cortex (M1). Arrows 
refer to connectivity studies. Increased (green arrows) and decreased (dotted red arrows) 
connectivity between the putamen and M1, pre-SMA/SMA, and primary sensory area (SM1) has 
been shown in patients with LID. 
 
Figure 4.  Main neurotransmitter terminals implicated in the induction of levodopa-
induced dyskinesia Within the striatum, dopaminergic terminals (red terminal) release 
dopamine while D2 autoreceptors and uptake processes also control synaptic DA levels. DA 
binds striatal postsynaptic D1 receptors inducing the formation of cAMP via adenylyl cyclase, 
which in turn favors the activation (black arrows) of PKA, able to phosphorylate and activate 
DA- and cAMP-regulated phosphoprotein of 32 KDa and ERK. Activated pERK induces an 
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abnormal activation of MSK-1 and the final phosphorylation of histone H3. p-DARPP-32 
inhibits (dotted lines) protein phosphatase 1. Glutamate is released from cortico-striatal terminals 
(light blue terminal) into the striatum and activates NMDA receptors, whose activity increases 
intracellular levels of Ca
2+
. Increased intracellular calcium levels facilitate the production and 
release of endocannabinoids which in turn act on CB1 receptors at presynaptic terminals, 
limiting glutamate release. Presynaptic modulation of glutamate and DA release is also achieved 
by the activation of opioid receptors. The serotonergic afferents (green terminal) release 
serotonin into the striatum which is regulated by 5-HT1 autoreceptors. These afferents take up 
levodopa, convert it to DA, and then release DA in an unregulated fashion. Finally, cholinergic 
acetylcholine interneurons (yellow terminal), by overstimulation of nACh receptors on 
dopaminergic terminals, contribute to the abnormal DA-release (see text for details and 
information on other mechanisms).  
5-HT = serotonin; 5-HT1 = 5-hydroxytryptamine receptor 1; AC = adenylyl cyclase; ACh = 
acetylcholine; ATP = Adenosine triphosphate; Ca2+ = calcium; cAMP = cyclic adenosine 
monophosphate; CB1 = cannabinoid receptor type 1; D1 = dopamine D1 receptor; D2 = 
dopamine D2 receptor; DA = dopamine; eCBs = endocannabinoids; GABA = gamma-
aminobutyric acid; GluN2A/2B = NMDA receptor subunits 2A and 2B ratio; eCBs = 
endocannabinoids; ER = endoplasmic reticulum; Glu = glutamate; MSK1 = mitogen- and stress-
activated kinase-1; nACh = nicotinic acetylcholine receptors; NMDA = N-methyl-D-aspartate; 
pERK = phospho-extracellular signal-regulated kinases; PDE10A = phosphodiesterase 10A; P-
H3 = phospho-histone H3; PKA = protein kinase A; p-DARPP-32 = phosphorylated dopamine- 
and cAMP-regulated phosphoprotein 32 kDa; PP1 = protein phosphatase 1; SPN = spiny 
projection neuron. 
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Supplementary Video legends 
 
Supplementary Video 1. Peak-dose dyskinesias as generalized chorea. This 58-year-old man 
with 10-year-history of PD demonstrates generalized chorea with arms and neck predominance. 
The movements are maximal during the peak-dose effect of levodopa and disappear in the 
wearing off/subtherapeutic window. Left arm dystonia is brought out during walking. 
 
Supplementary Video 2. Peak-dose dyskinesia predominantly in the legs. A 63-year-old man 
with 8-year history of PD demonstrates leg chorea with no or minimal upper-body involvement 
that is, by history, peak-dose in nature. 
 
Supplementary Video 3. Diphasic dyskinesia predominantly in the legs. This 56-year-old 
man with a 14-year history of PD, on treatment with levodopa-carbidopa enteral infusion, 
demonstrates leg-predominant chorea as a manifestation of diphasic dyskinesia. The movements 
disappear when levodopa infusion is increased, or an extra oral levodopa dose takes effect. 
 
Supplementary Video 4. This 52-year-old man with a 12-year history of PD demonstrates 
generalized chorea, suspected initially to represent peak-dose dyskinesia, but proven to be 
diphasic by its attenuation within minutes after subcutaneous apomorphine 0.2 mL (from 
Verhagen Metman and Espay, Neurology 2017) 
 
Supplementary Video 5. Early-morning (off) dystonia. Foot dystonia appears most 
prominently in the morning on the most affected side in this 64-year-old woman, shown here 8 
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years after symptom onset. Onset of action of levodopa eliminates the dystonia (not shown). 
Note intermittent episodes of resting hand tremor when sitting and walking, emphasizing under-
therapeutic medication state. 
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Table 1. Pathophysiology studies on levodopa-induced dyskinesia in humans. 
Year Subjects Methodology Outcome Measures 
Main findings in PD-LID vs PD-
no-LID  
2012
31
 HC = 10; PD-stable = 
17; PD-no-LID = 18;  
PD-LID = 20 
TMS LTP-like and LTD-like 
plasticity of most affected 
M1 
Lack of LTP-like plasticity and 
paradoxical potentiation after 
inhibitory TBS after acute LD 
challenge 
2016
29
  PD-LID = 2 LFP ECoG of M1 and LFP of 
STN 
60-90 Hz oscillations in M1 and 
STN and strong phase coherence 
between M1 and STN 
2013
102
 HC = 24; PD-no-LID = 
30; PD-LID = 29 
Structural 
MRI 
Cortical thickness (whole 
brain) 
↑ thickness in the right inferior 
frontal sulcus  
2013
102
 HC = 40; PD-no-LID = 
33; PD-LID = 33 
Structural 
MRI 
VBM and cortical thickness 
(ROI: IFC, cingulate 
cortex, SMA and pre-SMA, 
basal ganglia, SN, red 
nucleus, STN, cerebellum) 
↑ GM volume in IFC (bilateral) 
and midbrain in early onset  
PD-LID. ↑ GM volume in IFC 
(bilateral), SMA and pre-SMA in 
late onset PD-LID. ↑ cortical 
thickness of IFC (bilateral) in  
early onset PD-LID. ↑ cortical 
thickness of left IFC in late onset 
PD-LID 
2015
25
 fMRI: PD-no-LID = 12; 
PD-LID=12.  
TMS: PD-LID = 11 
RS-fMRI and 
TMS  
Functional connectivity of 
bilateral IFC, 
SMA/preSMA, M1, STN, 
thalamus, striatum and 
cerebellum.  
TBS (sham, inhibitory, 
facilitatory) over right IFC 
or M1 
↓connectivity of right IFC with left 
M1 and ↑connectivity of right IFC 
with right putamen in ON. 
Inhibitory TBS reduced LID when 
applied over the right IFC in PD-
LID 
2016
103
 PD-no-LID = 12;  
PD-LID = 12 
RS-fMRI + 
Structural 
MRI 
Functional connectivity and 
VBM (ROI: bilateral 
putamen, SMA, SM1, right 
IFC) 
 
↓connectivity after LD between 
SM1 and the putamen in the most 
affected hemisphere. ↓connectivity 
after LD between SMA and the 
putamen was correlated to LID 
severity. No structural abnormality 
in SM cortex, SMA, ICF, putamen 
2012
104
 PD-no-LID = 10;  
PD-LID = 10 
fMRI  Neural correlates of 
externally and internally 
triggered visuomotor tasks 
↑ activity in SMA and ↓ activity of 
right IFC during the visuomotor 
tasks, correlated to dyskinesia 
severity 
2015
105
 PD-no-LID = 12;  
PD LID = 12 
fMRI Neural correlates of 
successful and erroneous 
"Stop" responses in a stop-
signal reaction time 
During successful stop responses, 
↓ activity of right IFC in ON and ↑ 
activity of right IFC in OFF; 
during failed stop responses, ↑ 
activity of MFC in ON 
2014
106
 HC = 13;  
PD-no-LID = 13;  
PD LID = 13 
fMRI Neural correlates of GO 
and NoGO responses to 
stimulus-response mapping 
task 
↑ activity in preSMA and bilateral 
putamen in NoGo trials before 
developing LID. Finding 
correlated to severity of LID 
2015
26
 PD-no-LID = 13;  
PD LID = 13 
fMRI Functional connectivity 
between basal ganglia and 
M1 or pre-SMA during a 
visuomotor task  
LD ↑ connectivity between 
putamen and M1 during movement 
suppression (in a NoGo task). 
Finding correlated to severity of 
LID 
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Year Subjects Methodology Outcome Measures 
Main findings in PD-LID vs PD-
no-LID  
2012
32
 HC = 12;  
PD-drug naive = 9; 
PD-no-LID = 10;   
PD-LID = 10 
PET Binding of 
18
F-MK-9470, a 
selective radioligand for 
type 1 cannabinoid receptor  
No specific changes of type 1 
cannabinoid receptor in PD-LID, 
but only in the overall PD group 
compared to HC 
2014
82
 HC = 12;   
PD-no-LID = 12;  
PD-LID = 24 
PET Binding of: 
11
C-DASB, 5-
HT transporter; 
11
C-
raclopride, striatal DA 
levels. 
11
C-DASB binding in 
caudate/putamen comparable in 
PD-LID and PD-no-LID. ↑ striatal 
synaptic DA concentrations in PD-
LID, decreased by buspirone 
which induced an anti-dyskinetic 
effect   
2015
107
 PD-drug naive = 10;  
PD-no-LID = 10;  
PD-LID = 10 
PET Binding of: 
11
C-DASB,  
5-HT transporter; 
18
F-FP-
CIT, DA transporter. 
11
C-
DASB to 
18
F-FP-CIT 
binding ratio 
11
C-DASB to 
18
F-FP-CIT binding 
ratio ↑ in the putamen  
2015
108
 HC = 12;   
PD-no-LID = 12;  
PD-LID = 12 
PET Binding of: 
11
C-DASB, 5-
HT transporter; 
11
C-
raclopride, striatal DA 
levels. 
11
C-DASB to 
18
F-
FP-CIT binding ratio. ROI: 
globus pallidus 
11
C-DASB binding in globus 
pallidus ↓ in PD-no-LID compared 
to PD-LID and HC. ↑ pallidal 
synaptic DA in PD-LID  
2015
33
 HC = 12;  
PD-no-LID = 12;  
PD-LID = 12 
PET Binding of 
11
C-IMA107, a 
highly selective PDE10A 
ligand 
↓11C-IMA107 in caudate, 
substantia nigra and thalamic 
nuclei in PD-LID. ↓11C-IMA107 
in caudate and putamen correlated 
to more severe LID  
2016
34
 HC = 12;   
PD-no-LID = 11;  
PD-LID = 17 
PET Binding of: 
11
C-DASB, 5-
HT transporter; 
18
F-FP-
CIT, DA transporter. 
11
C-
DASB to  
18
F-FP-CIT binding ratio  
11
C-DASB to 
18
F-FP-CIT binding 
ratio ↑ in the putamen   
Only studies dated 2012 or older are included. 5-HT = 5-hydroxytryptamine (serotonin); AIMS = abnormal involuntary 
movement scale; BOLD = blood oxygenation level dependent; DA = dopamine; ECoG =  electrocorticography; fMRI= 
functional MRI; GM = grey matter; GPi= globus pallidus pars interna; HC = healthy controls; IFC = inferior frontal cortex; LD = 
levodopa; LFP = local field potential; LID = levodopa-induced dyskinesia; LTP = long-term potentiation; M1 = primary motor 
cortex; MFC = medial frontal cortex; NA = not available; PDE10A = phosphodiesterase 10A; PET = positron emission 
tomography; ROI = region of interest; RS = resting state; SM1 = primary sensorimotor cortex; SMA = supplementary motor area; 
SN = substantia nigra; STN = subthalamic nucleus; UPDRS = Unified Parkinson’s Disease Rating Scale; TBS = theta burst 
stimulation; TMS = transcranial magnetic stimulation; VBM = voxel based morphometry.  
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Table 2.  Therapies in clinical research development for levodopa-induced dyskinesia. 
 
Drug 
Mechanism of 
Action 
Dyskinesia 
Endpoint/ 
Duration 
Clinical Relevance 
ADS-5102 
(Amantadine 
extended release; GOCOVRI
™
) 
Glutamate 
antagonist 
(NMDA receptor 
antagonist) 
UDysRS / 12 
weeks 
Dose-dependent decrease in dyskinesia 
with secondary benefit of reduced OFF 
time.
1-3
 Approved by FDA in 2017 
Amantadine HCl Extended 
Release (OSMOLEX ER
™
) 
Glutamate 
antagonist 
(NMDA receptor 
antagonist) 
UDysRS / 98 days Phase III studies, NCT02153645 
(ALLAY-LID I ) / NCT02153632 
(ALLAY-LID II). No results published. 
Approved by FDA in 2018 based on PK 
equivalence with amantadine 
Dextromethorphan/Quinidine 
(AVP-923-45) 
 
Sigma-1 receptor-
agonist and 
glutamatergic/ 
monoaminergic 
modulator 
UDysRS / 2 
weeks 
Phase II crossover study, minimal 
clinical benefit (n = 13); well 
tolerated
109
 
Eltoprazine 
 
Serotonin agonist 
Mixed 5-HT1A/1B 
receptor agonist 
Clinical 
Dyskinesia Rating 
Scale; acute dose 
 
 
UDysRS / 84 days 
Phase IIa; acute dosing reduced peak-
dose dyskinesia (n=22) compared with 
placebo; no worsening of PD motor 
scores; AEs: nausea and dizziness
83
  
 
Phase IIb DBRCT; 2.5 – 7.5mg/d 
NCT02439125 Results pending    
Buspirone 5-HT1A receptor 
agonist  
AIMS / acute 
dose 
 
 
 
 
 
 
 
UDysRS / 12 
weeks  
 
 
 
Force plate 
measurements / 6-
h LD dose cycle 
UDysRS / 6 
weeks  
Subgroup from PET imaging study; 
acute dosing reduced LID during a 
levodopa challenge versus placebo (n = 
24); more effective in subjects with 
milder LID than with severe LID; no 
worsening of PD motor scores. AEs: 
drowsiness and dizziness
82
   
 
Phase III study; NCT02617017 
(BUSPARK) –evaluating efficacy of 
buspirone in PD-LID. Results pending 
 
Phase II study; NCT02589340 (BUS-
PD) – evaluating the efficacy of 
buspirone in combination with 
amantadine in reducing PD-LID. 
Results pending 
Foliglurax (PXT002331) Positive allosteric 
modulator of 
mGluR4 
Dyskinesia rating 
not defined. 
Hauser diary/28 
days 
Phase IIa study; NCT03162874 
(AMBLED) –for LID-PD and end of 
dose wearing off. Results pending  
Zonisamide  Channel modulator  UDysRS / 12 
weeks  
Phase IV open-label study; 
NCT03034538 – evaluating 2 doses for 
tolerability and efficacy for PD 
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dyskinesias. Results pending 
NLX-112 (befiradol or F13640) 5-HT1A receptor 
full agonist 
no information 
available 
Inhibits LID in rodent models of PD;
58
 
phase II study results pending 
IRL790  Dopamine D3 
receptor agonist 
UDysRS / 4 
weeks 
Phase IIa study; NCT03368170 –
evaluating IRL790 as an adjunctive 
treatment for PD-LID. Results pending 
 
. 
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